Evidence map›Paper›PMID 25201882›Full record

ArticleThe EMBO journal2014

Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.

Hyun Jin Cho, Jia Yu, Chengsong Xie, Parvathi Rudrabhatla, Xi Chen, Junbing Wu, Loukia Parisiadou, Guoxiang Liu, Lixin Sun, Bo Ma and 3 more

Open access · greenAbstract read
In one paragraph

Article in The EMBO journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Deficiency of Perry syndrome-associated p150NPJ Parkinson's disease · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Hyun Jin ChoTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Jia YuTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Chengsong XieTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Parvathi RudrabhatlaLaboratory of Neurochemistry and Laboratory of Neurobiology National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Xi ChenTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Junbing WuTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Loukia ParisiadouTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Guoxiang LiuTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Lixin SunTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Bo MaTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA.
Jinhui DingBioinformatics Core, Laboratory of Neurogenetics National Institute on Aging, Bethesda, MD, USA.
Zhihua LiuLaboratory of Immunology, National Institute of Allergy and Infectious Diseases National Institutes of Health, Bethesda, MD, USA Institute of Biophysics Chinese Academy of Sciences, Beijing, China zhihualiu@ibp.ac.cn caih@mail.nih.gov.
Huaibin CaiTransgenics Section, Laboratory of Neurogenetics National Institute on Aging National Institutes of Health, Bethesda, MD, USA zhihualiu@ibp.ac.cn caih@mail.nih.gov.
National Institute on Aging · USNational Institutes of Health · USInstitute of Biophysics · CNNational Institute of Neurological Disorders and Stroke · US

Funding

The Function and Pathogenic Mechanisms of LRRK2/Dardarin in Parkinson's DiseaseZIAAG000944 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2009 to 2025
$10.2M
The Function and Pathogenic Mechanisms of LRRK2/Dardarin in Parkinson's DiseaseZ01AG000944 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2008 to 2008
$499k
Intramural NIH HHS Z01 AG000944
6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) has been associated with Parkinson's disease (PD) and other disorders. However, its normal physiological functions and pathogenic properties remain elusive. Here we show that LRRK2 regulates the anterograde ER-Golgi transport through anchoring Sec16A at the endoplasmic reticulum exit sites (ERES). LRRK2 interacted and co-localized with Sec16A, a key protein in the formation of ERES. Lrrk2 depletion caused a dispersion of Sec16A from ERES and impaired ER export. In neurons, LRRK2 and Sec16A showed extensive co-localization at the dendritic ERES (dERES) that locally regulate the transport of proteins to the dendritic spines. A loss of Lrrk2 affected the association of Sec16A with dERES and impaired the activity-dependent targeting of glutamate receptors onto the cell/synapse surface. Furthermore, the PD-related LRRK2 R1441C missense mutation in the GTPase domain interfered with the interaction of LRRK2 with Sec16A and also affected ER-Golgi transport, while LRRK2 kinase activity was not required for these functions. Therefore, our findings reveal a new physiological function of LRRK2 in ER-Golgi transport, suggesting ERES dysfunction may contribute to the pathogenesis of PD.

Indexed as

AnimalsCell LineCells, CulturedCOP-Coated VesiclesDendritic SpinesEndoplasmic ReticulumGene Expression RegulationGenes, ReporterGolgi ApparatusHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceModels, BiologicalMutation, MissenseParkinson DiseaseProtein Interaction MappingLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Serine-Threonine KinasesRecombinant Fusion ProteinsSEC16A protein, humanVesicular Transport Proteinsdendritic ERES (dERES)ER exit sites (ERES)ER–Golgi transportLeucine‐rich repeat kinase 2 (LRRK2)Sec16A

Identifiers

PMID25201882
PMCPMC4253522
OpenAlexW2083438412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.